{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:41:16Z","timestamp":1792269676599,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.yexmp.2024.104900","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T20:32:40Z","timestamp":1715286760000},"page":"104900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Urinary soluble CD163 is a putative non-invasive biomarker for primary sclerosing cholangitis"],"prefix":"10.1016","volume":"137","author":[{"given":"Tanja","family":"Elger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Fererberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Huss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Sommersberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Stoeckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gunawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Liebisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kandulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Buechler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke Christian","family":"Tews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2024.104900_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071492","article-title":"The current status of molecular biomarkers for inflammatory bowel disease","volume":"10","author":"Alghoul","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.yexmp.2024.104900_bb0010","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.rdc.2018.06.007","article-title":"Renal manifestations of inflammatory bowel disease","volume":"44","author":"Ambruzs","year":"2018","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.yexmp.2024.104900_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061801","article-title":"Role of human macrophage polarization in inflammation during infectious diseases","volume":"19","author":"Atri","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2024.104900_bb0020","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000315","article-title":"Circulating macrophage activation markers predict transplant-free survival in patients with primary Sclerosing cholangitis","volume":"12","author":"Bossen","year":"2021","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0025","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/j.1572-0241.2007.01343.x","article-title":"The immune response in inflammatory bowel disease","volume":"102","author":"Brown","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/18715281113126660060","article-title":"Diagnostic and prognostic potential of the macrophage specific receptor CD163 in inflammatory diseases","volume":"12","author":"Buechler","year":"2013","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"10.1016\/j.yexmp.2024.104900_bb0035","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fmed.2020.00115","article-title":"The emerging role of macrophages in chronic Cholangiopathies featuring biliary fibrosis: an attractive therapeutic target for orphan diseases","volume":"7","author":"Cadamuro","year":"2020","journal-title":"Front. Med. (Lausanne)."},{"key":"10.1016\/j.yexmp.2024.104900_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030800","article-title":"On-treatment decrease of serum Interleukin-6 as a predictor of clinical response to biologic therapy in patients with inflammatory bowel diseases","volume":"9","author":"Caviglia","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.yexmp.2024.104900_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044328","article-title":"Fecal lipocalin 2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation","volume":"7","author":"Chassaing","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.yexmp.2024.104900_bb0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/ard.2003.018382","article-title":"Colon mucosa of patients both with spondyloarthritis and Crohn\u2019s disease is enriched with macrophages expressing the scavenger receptor CD163","volume":"64","author":"Demetter","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.yexmp.2024.104900_bb0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/sji.12222","article-title":"Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-alpha antibody treatment in active inflammatory bowel disease","volume":"80","author":"Dige","year":"2014","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0060","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.936497","article-title":"Renal manifestations in inflammatory bowel disease: a cohort study during the biologic era","volume":"28","author":"Dincer","year":"2022","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.yexmp.2024.104900_bb0065","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","author":"EASL, C. P. G. o. s. c","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0070","article-title":"Clinical significance of soluble hemoglobin scavenger receptor CD163 (sCD163) in sepsis, a prospective study","volume":"7","author":"Feng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.yexmp.2024.104900_bb0075","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/oby.20376","article-title":"The macrophage-specific serum marker, soluble CD163, is increased in obesity and reduced after dietary-induced weight loss","volume":"21","author":"Fjeldborg","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.yexmp.2024.104900_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069839","article-title":"Lesional accumulation of CD163-expressing cells in the gut of patients with inflammatory bowel disease","volume":"8","author":"Franze","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.yexmp.2024.104900_bb0085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.disamonth.2017.07.001","article-title":"A comprehensive review and update on Crohn\u2019s disease","volume":"64","author":"Gajendran","year":"2018","journal-title":"Dis. Mon."},{"key":"10.1016\/j.yexmp.2024.104900_bb0090","article-title":"Macrophage activation markers, soluble CD163 and mannose receptor, in liver fibrosis","volume":"7","author":"Gantzel","year":"2020","journal-title":"Front. Med. (Lausanne)."},{"key":"10.1016\/j.yexmp.2024.104900_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.769802","article-title":"Urinary soluble CD163 levels predict IgA nephropathy remission status","volume":"12","author":"Gong","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0100","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s10067-020-05343-6","article-title":"Urinary soluble CD163 is a good biomarker for renal disease activity in lupus nephritis","volume":"40","author":"Gupta","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0105","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1021\/acs.analchem.6b02596","article-title":"Relevance in the use of appropriate internal standards for accurate quantification using LC-MS\/MS: Tauro-conjugated bile acids as an example","volume":"88","author":"Krautbauer","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.yexmp.2024.104900_bb0110","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1055\/a-1015-7048","article-title":"Aktualisierung der S3-Leitlinie Colitis ulcerosa 2019","volume":"57","author":"Kucharzik","year":"2019","journal-title":"Z. Gastroenterol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0115","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMra1506330","article-title":"Primary Sclerosing cholangitis","volume":"375","author":"Lazaridis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexmp.2024.104900_bb0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5217\/ir.2018.16.1.26","article-title":"Immunological pathogenesis of inflammatory bowel disease","volume":"16","author":"Lee","year":"2018","journal-title":"Intest Res."},{"key":"10.1016\/j.yexmp.2024.104900_bb0125","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.me.39.020188.002341","article-title":"Serum creatinine and renal-function","volume":"39","author":"Levey","year":"1988","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.yexmp.2024.104900_bb0130","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000007116","article-title":"Incidence, prevalence, and natural history of primary sclerosing cholangitis in the United Kingdom","volume":"96","author":"Liang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.yexmp.2024.104900_bb0135","first-page":"124","article-title":"Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence","volume":"32","author":"Mertz","year":"2019","journal-title":"Ann. Gastroenterol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0140","first-page":"178","article-title":"Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: from laboratory to clinic","volume":"8","author":"Moein","year":"2017","journal-title":"Caspian J. Intern. Med."},{"key":"10.1016\/j.yexmp.2024.104900_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365513.2011.626868","article-title":"Soluble CD163","volume":"72","author":"Moller","year":"2012","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.yexmp.2024.104900_bb0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00365510310000439","article-title":"Biological variation of soluble CD163","volume":"63","author":"Moller","year":"2003","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.yexmp.2024.104900_bb0155","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/JLB.3A1218-500R","article-title":"The macrophage-related biomarkers sCD163 and sCD206 are released by different shedding mechanisms","volume":"106","author":"Nielsen","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0160","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1515\/cclm-2020-0466","article-title":"Urine soluble CD163 (sCD163) as biomarker in glomerulonephritis: stability, reference interval and diagnostic performance","volume":"59","author":"Nielsen","year":"2021","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.yexmp.2024.104900_bb0165","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1053\/j.sult.2022.06.007","article-title":"Practical guide for radiological diagnosis of primary and secondary Sclerosing cholangitis","volume":"43","author":"Pria","year":"2022","journal-title":"Semin. Ultrasound CT MR"},{"key":"10.1016\/j.yexmp.2024.104900_bb0170","article-title":"Heme Oxygenase-1: an anti-inflammatory effector in cardiovascular, lung, and related metabolic disorders","volume":"11","author":"Ryter","year":"2022","journal-title":"Antioxidants (Basel)."},{"key":"10.1016\/j.yexmp.2024.104900_bb0175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.cyto.2018.05.017","article-title":"Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis","volume":"110","author":"Sakumura","year":"2018","journal-title":"Cytokine"},{"issue":"1275\u20131285","key":"10.1016\/j.yexmp.2024.104900_bb0180","article-title":"Biomarkers of inflammation in inflammatory bowel disease","volume":"149","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.yexmp.2024.104900_bb0185","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1016\/j.jchromb.2009.09.038","article-title":"Rapid quantification of bile acids and their conjugates in serum by liquid chromatography-tandem mass spectrometry","volume":"877","author":"Scherer","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.yexmp.2024.104900_bb0190","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12944-023-01971-4","article-title":"Altered fecal bile acid composition in active ulcerative colitis","volume":"22","author":"Sommersberger","year":"2023","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.yexmp.2024.104900_bb0195","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/j.1365-2362.2009.02170.x","article-title":"Adiponectin downregulates CD163 whose cellular and soluble forms are elevated in obesity","volume":"39","author":"Sporrer","year":"2009","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.yexmp.2024.104900_bb0200","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects","volume":"13","author":"Sturm","year":"2019","journal-title":"J. Crohns Coliti."},{"key":"10.1016\/j.yexmp.2024.104900_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041186","article-title":"Fecal and urinary Adipokines as disease biomarkers","volume":"11","author":"Tews","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.yexmp.2024.104900_bb0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1177\/2050640617708953","article-title":"The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease","volume":"6","author":"Torres","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.yexmp.2024.104900_bb0215","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/pin.12794","article-title":"Prediction of steroid demand in the treatment of patients with ulcerative colitis by immunohistochemical analysis of the mucosal microenvironment and immune checkpoint: role of macrophages and regulatory markers in disease severity","volume":"69","author":"Tsuda","year":"2019","journal-title":"Pathol. Int."},{"key":"10.1016\/j.yexmp.2024.104900_bb0220","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CEG.S186097","article-title":"A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis","volume":"12","author":"Vaughn","year":"2019","journal-title":"Clin. Exp. Gastroenterol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0225","first-page":"527","article-title":"New insights into the pathogenesis of Crohn\u2019s disease: are they relevant for therapeutic options?","volume":"139","author":"Vavricka","year":"2009","journal-title":"Swiss Med. Wkly."},{"key":"10.1016\/j.yexmp.2024.104900_bb0230","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","article-title":"Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities","volume":"55","author":"Vesterhus","year":"2020","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41598-017-18305-x","article-title":"Reprogramming of pro-inflammatory human macrophages to an anti-inflammatory phenotype by bile acids","volume":"8","author":"Wammers","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexmp.2024.104900_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2020.1819155","article-title":"Gut microbial bile acid metabolite skews macrophage polarization and contributes to high-fat diet-induced colonic inflammation","volume":"12","author":"Wang","year":"2020","journal-title":"Gut Microbes"},{"key":"10.1016\/j.yexmp.2024.104900_bb0245","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2265.2011.04284.x","article-title":"Relationship between monocyte\/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects","volume":"77","author":"Zanni","year":"2012","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0250","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3389\/fimmu.2020.00671","article-title":"Association of Urine sCD163 with proliferative lupus nephritis, Fibrinoid necrosis, cellular crescents and intrarenal M2 macrophages","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2024.104900_bb0255","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1177\/02698811221089041","article-title":"Hyodeoxycholic acid inhibits lipopolysaccharide-induced microglia inflammatory responses through regulating TGR5\/AKT\/NF-kappaB signaling pathway","volume":"36","author":"Zhu","year":"2022","journal-title":"J. Psychopharmacol."}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480024000194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480024000194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:46:53Z","timestamp":1718412413000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480024000194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":51,"alternative-id":["S0014480024000194"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2024.104900","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary soluble CD163 is a putative non-invasive biomarker for primary sclerosing cholangitis","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2024.104900","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104900"}}